Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
epicept.com

See what CB Insights has to offer

Founded Year

1993

Stage

Merger | Merged

Total Raised

$66.85M

About EpiCept

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

EpiCept Headquarter Location

777 Old Saw Mill River Road

Tarrytown, New York, 10591,

United States

914-606-3500

Latest EpiCept News

Immune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review Report Updated 07082017 Prices from USD $300

Aug 20, 2017

Printed From BioPortfolio.com Immune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300 18:34 EDT 20 Aug 2017 | BioPortfolio Reports Home » Topics » Antibodies » Latest News » Immune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300 Summary Immune Pharmaceuticals Inc Immune Pharma formerly EpiCept Corporation, is a pharmaceutical company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer . The company's bertilimumab is under clinical development for moderate to severe ulcerative colitis , crohn's disease and bullous pemphigoid. It also offers nanomabs, which is an antibody nanoparticle conjugate technology platform for the targeted delivery of chemotherapeutics. Immune Pharma's crolibulin is a small molecule vascular disrupting agent that is used for the treatment of solid tumors. The company develops drugs in the areas of immuno oncology, nanodermatology and neuropathic pain. It has research and development facility in HerzliyaPituach, Israel. Immune Pharma is headquartered in New York, the US. Immune Pharmaceuticals Inc Key Recent Developments Jul 19,2017: Immune Pharmaceuticals Provides Update on Plan to Implement a Spinoff of Cytovia into a Separate Publicly Traded Oncology Company Apr 24,2017: Immune Pharmaceuticals Announces Corporate Restructuring Mar 13,2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement Jan 27,2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors Oct 17,2016: Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary This comprehensive SWOT profile of Immune Pharmaceuticals Inc provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Immune Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends. The profile contains critical company information including*, x000D x000D Business description A detailed description of the company's operations and business divisions.x000D Corporate strategy Analyst's summarization of the company's business strategy.x000D SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D Company history Progression of key events associated with the company.x000D Major products and services A list of major products, services and brands of the company.x000D Key competitors A list of key competitors to the company.x000D Key employees A list of the key executives of the company.x000D Executive biographies A brief summary of the executives' employment history.x000D Key operational heads A list of personnel heading key departments/functions.x000D Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D Key manufacturing facilities A list of key manufacturing facilities of the company.x000D Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D x000D Note*: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include,x000D x000D You get detailed information about the company and its operations to identify potential customers and suppliers.x000D The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D x000D Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D x000D Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D x000D Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D x000D Gain key insights into the company for academic or business research.x000D Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. Related Biotechnology, Pharmaceutical and Healthcare News

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EpiCept

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EpiCept is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

EpiCept Patents

EpiCept has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/3/2007

11/30/2010

Transcription factors, Programmed cell death, Triazines, Proteins, EC 3.4.22

Grant

Application Date

7/3/2007

Grant Date

11/30/2010

Title

Related Topics

Transcription factors, Programmed cell death, Triazines, Proteins, EC 3.4.22

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.